Thursday, 13 June 2013

Eltrombopag for chronic immune (idiopathic) thrombocytopenic purpura

NICE publishes final draft guidance for eltrombopag (Revolade, GlaxoSmithKline) an option in ITP.

Eltrombopag is a thrombopoietin-receptor agonist [1]. It has been used in ITP [2] and also in Hepatitis C infection where patients with thrombocytopenia would otherwise be excluded from treatment with Interferon [3].

1. Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr. Opin. Hematol. 2012 Sep;19(5):392–398. Available from:

2. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 2007 Nov;357(22):2237–2247. Available from:

3. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N. Engl. J. Med. 2007 Nov;357(22):2227–2236. Available from:

No comments:

Post a Comment